M Pharmaceutical Inc (CNSX:MQ) will substantially increase its sales infrastructure, R&D and look overseas to boost over-the-counter sales at its latest acquisition, said chief executive Gary Thompson.
The Canadian group announced the deal to acquire Cincinatti-based 40Js on 4 January and is going through regulatory and due diligence, but expects to close it this month.
“Once rebranded and relaunched, these innovative topical formulations of L-Arginine, menthol and other key ingredients will provide millions of women with more natural solutions to inadequate arousal, vaginal dryness and painful intercourse, as well as other healthcare concerns” Thompson said.
“Successfully sold outside of the US for 15 years and recently reformulated to be paraben free, these OTC products are now ready for a much larger audience seeking treatments for these all too common issues.
“Our plans call for a multi-channel, multi-product approach, including contracting with several distribution partners for branded and private label distribution, a renewed focus on primary-care physician partnerships combined with building a significant direct-to-consumer sales strategy.”
Story by ProactiveInvestors